RIVER At Home Ketamine Protocols

Conditions studied

Chronic Condition, Chronic Pain, Chronic Disease, Major Depressive Disorder, Post Traumatic Stress Disorder, Anxiety Disorders

About this study

Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and behavior. However, the existence of multiple risk factors also means that there are numerous ways to intervene. Addressing and improving even one risk area will reverberate and improve other areas and the quality of life. RIVER Foundation is completing a 500-participant pilot study researching the safety of oral and nasal ketamine at home with no therapy. The pilot study examined three psychological scales: P.H.Q. 9, G.A.D. 7, and PCL5 scores. The interim report will be available in Nov 2023 with a final report in June 2024. The lack of knowledge for the average medical practitioner makes ketamine a boutique medicine, often costly and unaffordable to those in need. Yet daily medical providers are eliminating ketamine as a choice in the treatment of chronic conditions. The pilot study demonstrated the who, and where. The who, was adults with a chronic condition. The pilot study demonstrated the majority of those who could use ketamine are not receiving it due to cost. According to the 500-participant study, ketamine is safe and effective for at-home use thus demonstrating the where (at home with no supervision).

Interventions

• Drug: Ketamine — The use of ketamine in chronic conditions.

Primary outcomes

• Mental Health PHQ9 (Through study completion, an average of 5 years)
• Mental Health GAD7 (Through study completion, an average of 5 years)
• Mental Health PCL5 (Through study completion, an average of 5 years)

Eligibility information

Study locations

• RIVER Foundation, Bigfork, Montana 59911 United States
• RIVER Telehealth, Helena, Montana 59601 United States